The acute agitation and aggression treatment market size has grown strongly in recent years. It will grow from $5.72 billion in 2024 to $6.05 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to advances in pharmacology, rise in clinical research, regulatory approvals, rise in prevalence of acute agitation and aggression cases, increased awareness regarding mental health.
The acute agitation and aggression treatment market size is expected to see strong growth in the next few years. It will grow to $7.77 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to growing aging population, growing healthcare infrastructure, rising pharmaceutical industry investment, rise in home-base care, rise in disposable income. Major trends in the forecast period include non-pharmacological interventions, precision medicine, ai and predictive analytics, community-based support, industry collaboration.
The anticipated expansion of the acute agitation and aggression treatment market is closely tied to several significant factors. Firstly, the increasing incidence of dementia is expected to be a driving force. Dementia, a condition marked by cognitive impairments and an inability to perform daily tasks, often leads to symptoms like agitation and restlessness. Effective treatment is crucial in managing these symptoms, improving the patient's quality of life, and addressing the root causes of agitation. For instance, according to data from the Australian Institute of Health and Welfare in February 2023, Australia is expected to see a substantial rise in dementia cases, reaching 849,300 by 2058, highlighting the need for treatments in this area.
The growing prevalence of mental illness is expected to drive the expansion of the acute agitation and aggression treatment market in the coming years. Mental illness refers to medical conditions that affect an individual's cognitive, emotional, psychological, or behavioral functions. These conditions often necessitate treatments for acute agitation and aggression to manage disruptive and potentially harmful behaviors, ensuring both the safety of the affected individual and those around them, while also addressing the underlying psychological distress and promoting overall well-being. For example, in December 2023, according to the NHS Business Services Authority, a US-based non-departmental public body, antidepressant prescriptions increased by 1.5%, reaching 22 million, with 6.8 million patients. There were also increases in prescriptions for hypnotics, anxiolytics, and psychosis drugs, with dementia medications seeing the largest rise, up 3.1% to 1.1 million items. As a result, the growing burden of mental illness is driving the demand for acute agitation and aggression treatments.
Major companies within the acute agitation and aggression treatment market are actively engaged in innovative product development and approvals, exemplified by IGALMI (dexmedetomidine). IGALMI, a sublingual film, has received FDA approval and offers a new treatment avenue for individuals dealing with agitation associated with schizophrenia or bipolar disorders. Developed by BioXcel Therapeutics Inc. in April 2022, this fast-acting and short-duration medication represents an advancement in addressing severe or life-threatening conditions. These developments contribute to the evolving landscape of treatments within the market.
Major companies operating in the acute agitation and aggression treatment market are focusing on developing innovative products, such as a generic version of Zyprexa, to address the needs of patients. Generic Zyprexa is a version of the brand-name drug Zyprexa, which contains the active ingredient olanzapine and is used to treat psychotic conditions. For instance, in September 2023, Camber Pharmaceuticals, a US-based pharmaceutical company, launched a generic version of Zyprexa. This atypical antipsychotic drug is indicated for the treatment of acute agitation associated with schizophrenia and bipolar I mania.
In April 2023, SK Capital Partners LP, a private investment firm based in the United States, completed the acquisition of Apotex Inc., a renowned Canada-based generic pharmaceutical company. The acquisition, for an undisclosed sum, represents a strategic move enabling SK Capital to broaden its presence within the generic pharmaceutical sector. Apotex's specialization in producing medications for treating acute agitation and aggression aligns with SK Capital's extended investment pursuits in the healthcare industry.
Treatment for acute agitation and aggression addresses the sudden onset of restlessness, irritability, and hostility in patients, aiming to manage and alleviate these symptoms. Such behaviors can be manifestations of underlying conditions like psychiatric disorders, neurological issues, or substance use or withdrawal effects.
The primary methods for managing acute agitation and aggression encompass behavioral, environmental, and pharmacological approaches. The behavioral approach involves the scientific study of observable behavior and its environmental triggers, emphasizing psychological perspectives. Pharmacologic approaches often employ diverse drugs, such as anti-psychotics, benzodiazepines, and others, administered through various routes like oral or intramuscular. These treatments target conditions such as schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation, alcohol withdrawal, and more. They are utilized across various settings, including hospitals, ambulatory surgical centers, psychiatric care facilities, and other healthcare environments.
The acute agitation and aggression treatment market research report is one of a series of new reports that provides acute agitation and aggression treatment market statistics, including acute agitation and aggression treatment industry global market size, regional shares, competitors with acute agitation and aggression treatment market share, detailed acute agitation and aggression treatment market segments, market trends and opportunities, and any further data you may need to thrive in the acute agitation and aggression treatment industry. This acute agitation and aggression treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Major companies operating in the acute agitation and aggression treatment market include Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Ono Pharmaceutical Co Ltd., Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc., Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc.
North America was the largest region in the acute agitation and aggression treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute agitation and aggression treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the acute agitation and aggression treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The acute agitation and aggression treatment market includes revenues earned by entities by providing treatment with de-escalation techniques, psychosocial support, and medical evaluation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute agitation and aggression treatment market also consists of sales of lorazepam, chlorpromazine, and quetiapine API, droperidol, olanzapine, and ziprasidone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The acute agitation and aggression treatment market size is expected to see strong growth in the next few years. It will grow to $7.77 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to growing aging population, growing healthcare infrastructure, rising pharmaceutical industry investment, rise in home-base care, rise in disposable income. Major trends in the forecast period include non-pharmacological interventions, precision medicine, ai and predictive analytics, community-based support, industry collaboration.
The anticipated expansion of the acute agitation and aggression treatment market is closely tied to several significant factors. Firstly, the increasing incidence of dementia is expected to be a driving force. Dementia, a condition marked by cognitive impairments and an inability to perform daily tasks, often leads to symptoms like agitation and restlessness. Effective treatment is crucial in managing these symptoms, improving the patient's quality of life, and addressing the root causes of agitation. For instance, according to data from the Australian Institute of Health and Welfare in February 2023, Australia is expected to see a substantial rise in dementia cases, reaching 849,300 by 2058, highlighting the need for treatments in this area.
The growing prevalence of mental illness is expected to drive the expansion of the acute agitation and aggression treatment market in the coming years. Mental illness refers to medical conditions that affect an individual's cognitive, emotional, psychological, or behavioral functions. These conditions often necessitate treatments for acute agitation and aggression to manage disruptive and potentially harmful behaviors, ensuring both the safety of the affected individual and those around them, while also addressing the underlying psychological distress and promoting overall well-being. For example, in December 2023, according to the NHS Business Services Authority, a US-based non-departmental public body, antidepressant prescriptions increased by 1.5%, reaching 22 million, with 6.8 million patients. There were also increases in prescriptions for hypnotics, anxiolytics, and psychosis drugs, with dementia medications seeing the largest rise, up 3.1% to 1.1 million items. As a result, the growing burden of mental illness is driving the demand for acute agitation and aggression treatments.
Major companies within the acute agitation and aggression treatment market are actively engaged in innovative product development and approvals, exemplified by IGALMI (dexmedetomidine). IGALMI, a sublingual film, has received FDA approval and offers a new treatment avenue for individuals dealing with agitation associated with schizophrenia or bipolar disorders. Developed by BioXcel Therapeutics Inc. in April 2022, this fast-acting and short-duration medication represents an advancement in addressing severe or life-threatening conditions. These developments contribute to the evolving landscape of treatments within the market.
Major companies operating in the acute agitation and aggression treatment market are focusing on developing innovative products, such as a generic version of Zyprexa, to address the needs of patients. Generic Zyprexa is a version of the brand-name drug Zyprexa, which contains the active ingredient olanzapine and is used to treat psychotic conditions. For instance, in September 2023, Camber Pharmaceuticals, a US-based pharmaceutical company, launched a generic version of Zyprexa. This atypical antipsychotic drug is indicated for the treatment of acute agitation associated with schizophrenia and bipolar I mania.
In April 2023, SK Capital Partners LP, a private investment firm based in the United States, completed the acquisition of Apotex Inc., a renowned Canada-based generic pharmaceutical company. The acquisition, for an undisclosed sum, represents a strategic move enabling SK Capital to broaden its presence within the generic pharmaceutical sector. Apotex's specialization in producing medications for treating acute agitation and aggression aligns with SK Capital's extended investment pursuits in the healthcare industry.
Treatment for acute agitation and aggression addresses the sudden onset of restlessness, irritability, and hostility in patients, aiming to manage and alleviate these symptoms. Such behaviors can be manifestations of underlying conditions like psychiatric disorders, neurological issues, or substance use or withdrawal effects.
The primary methods for managing acute agitation and aggression encompass behavioral, environmental, and pharmacological approaches. The behavioral approach involves the scientific study of observable behavior and its environmental triggers, emphasizing psychological perspectives. Pharmacologic approaches often employ diverse drugs, such as anti-psychotics, benzodiazepines, and others, administered through various routes like oral or intramuscular. These treatments target conditions such as schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation, alcohol withdrawal, and more. They are utilized across various settings, including hospitals, ambulatory surgical centers, psychiatric care facilities, and other healthcare environments.
The acute agitation and aggression treatment market research report is one of a series of new reports that provides acute agitation and aggression treatment market statistics, including acute agitation and aggression treatment industry global market size, regional shares, competitors with acute agitation and aggression treatment market share, detailed acute agitation and aggression treatment market segments, market trends and opportunities, and any further data you may need to thrive in the acute agitation and aggression treatment industry. This acute agitation and aggression treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Major companies operating in the acute agitation and aggression treatment market include Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Ono Pharmaceutical Co Ltd., Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc., Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc.
North America was the largest region in the acute agitation and aggression treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute agitation and aggression treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the acute agitation and aggression treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The acute agitation and aggression treatment market includes revenues earned by entities by providing treatment with de-escalation techniques, psychosocial support, and medical evaluation. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute agitation and aggression treatment market also consists of sales of lorazepam, chlorpromazine, and quetiapine API, droperidol, olanzapine, and ziprasidone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Acute Agitation and Aggression Treatment Market Characteristics3. Acute Agitation and Aggression Treatment Market Trends and Strategies4. Acute Agitation and Aggression Treatment Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Acute Agitation and Aggression Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Acute Agitation and Aggression Treatment Market34. Recent Developments in the Acute Agitation and Aggression Treatment Market
5. Global Acute Agitation and Aggression Treatment Growth Analysis and Strategic Analysis Framework
6. Acute Agitation and Aggression Treatment Market Segmentation
7. Acute Agitation and Aggression Treatment Market Regional and Country Analysis
8. Asia-Pacific Acute Agitation and Aggression Treatment Market
9. China Acute Agitation and Aggression Treatment Market
10. India Acute Agitation and Aggression Treatment Market
11. Japan Acute Agitation and Aggression Treatment Market
12. Australia Acute Agitation and Aggression Treatment Market
13. Indonesia Acute Agitation and Aggression Treatment Market
14. South Korea Acute Agitation and Aggression Treatment Market
15. Western Europe Acute Agitation and Aggression Treatment Market
16. UK Acute Agitation and Aggression Treatment Market
17. Germany Acute Agitation and Aggression Treatment Market
18. France Acute Agitation and Aggression Treatment Market
19. Italy Acute Agitation and Aggression Treatment Market
20. Spain Acute Agitation and Aggression Treatment Market
21. Eastern Europe Acute Agitation and Aggression Treatment Market
22. Russia Acute Agitation and Aggression Treatment Market
23. North America Acute Agitation and Aggression Treatment Market
24. USA Acute Agitation and Aggression Treatment Market
25. Canada Acute Agitation and Aggression Treatment Market
26. South America Acute Agitation and Aggression Treatment Market
27. Brazil Acute Agitation and Aggression Treatment Market
28. Middle East Acute Agitation and Aggression Treatment Market
29. Africa Acute Agitation and Aggression Treatment Market
30. Acute Agitation and Aggression Treatment Market Competitive Landscape and Company Profiles
31. Acute Agitation and Aggression Treatment Market Other Major and Innovative Companies
35. Acute Agitation and Aggression Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Acute Agitation and Aggression Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on acute agitation and aggression treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for acute agitation and aggression treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute agitation and aggression treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Treatment Approach: Behavioral Approaches; Environmental Interventions; Pharmacologic Approaches2) By Drug Class: Anti-Psychotics; Benzodiazepines; Other Drug Classes
3) By Route of Administration: Oral; Intramuscular; Other Routes of Administrations
4) By Indication: Schizophrenia; Dementia; Bipolar Disorder; Depression; Drug-Induced Agitation and Aggression; Alcohol Withdrawal; Other Indications
5) By End User: Hospitals and Ambulatory Surgical Centers; Psychiatric Care Facilities; Other End Users
Subsegments:
1) By Box Style: Standard Box Action Cameras; Modular Box Action Cameras2) By Cube Style: Compact Cube Action Cameras; Cube Cameras with Integrated Mounts
3) By Bullet Style: Long, Cylindrical Action Cameras; Mountable Bullet Cameras
4) By Periscope & 360°: 360-Degree Cameras; Periscope Cameras
5) By Other Types: Wearable Action Cameras; Drone Action Cameras; Specialty Action Cameras
Key Companies Mentioned: Pfizer Inc.;Johnson and Johnson Pvt Ltd.;F Hoffmann-La Roche Ltd.;AbbVie Inc.;Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Acute Agitation and Aggression Treatment market report include:- Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Ono Pharmaceutical Co Ltd., Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc., Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 6.05 Billion |
| Forecasted Market Value ( USD | $ 7.77 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
